Benzinga | Nov 2, 2020 07:59AM EST

H.C. Wainwright Maintains Buy on Mirati Therapeutics, Lowers Price Target to $233

H.C. Wainwright analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $238 to $233.